Loading…
← CockpitCompetitor Analysis › SOBI.ST Swedish Orphan Biovitrum ABOpen in the cockpit ↗

Swedish Orphan Biovitrum ABSOBI.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Pharmaceuticals: Major

Swedish biopharmaceutical company developing and selling treatments for rare diseases, especially hemophilia and immunology.

≈ A Swedish Alexion Pharmaceuticals/UltragenyxMomentum neutral 59
Mkt cap
$16.1B
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$23.6M
20-day average traded
Fwd P/E
24.1×
forward earnings
ROIC−WACC
+7.7 pp
WACC 5.0%
Hurdle
-15 pp
Req g minus delivered
Next earnings
78 days
4 Feb 2027
Close · SEKSEK 474.20
1D+0.3%
1W-2.4%
1M+6.2%
3M+3.1%
6M+6.0%
YTD+42.5%
1Y+39.4%
ATR %2.6%
52w lowhigh6.5% off high

What Swedish Orphan Biovitrum does

Swedish biopharmaceutical company developing and selling treatments for rare diseases, especially hemophilia and immunology.

Sells rare-disease medicines to hospital specialists, many licensed in from other companies or bought rather than discovered itself; for example, it sells hemophilia drugs Elocta and Alprolix outside the US under an agreement with their original developer. Growth therefore comes from adding products and taking them to new countries.

In one line: A Swedish Alexion Pharmaceuticals/Ultragenyx.

Products and services

  • Hemophilia treatments
  • Immunology therapies
  • Specialty care (other rare disease drugs)

Customers

  • Hospitals/hematology specialists
  • Healthcare payers

Where it sits in the supply chain

  • Health care
  • Biopharmaceuticals (rare disease)
  • Rare disease drug development…

What could go right

  • New rare-disease drug launches
  • Hemophilia treatment market growth

What could go wrong

  • Patent expiry/biosimilar competition
  • Drug pricing pressure

Moat: narrow (IP / patents, regulatory licence). Orphan-drug exclusivity and specialist physician relationships in niche rare-disease areas.

Headquarters: Stockholm, Sweden · Founded: 1996 · Employees: 1,888

Named competitors

Swedish Orphan Biovitrum at a glance

Size Swedish Orphan Biovitrum (SOBI.ST) is a Sweden Health Care company (Pharmaceuticals: Major) with a market value of $16.1B, the 19th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 474.20 on 18 Nov 2026.

Performance Over six months the shares gained 6.0%, against +4.4% for the median peer and +2.8% for the Sweden market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 14.8% over the last twelve months (peer median +18.8%); the operating margin is 30.4% (peer median 21.3%).

Valuation It trades at 24.1× forward earnings against a peer median of 28.0× (10th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -15 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 7.7 points above its cost of capital (5.0% WACC).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011021 May 202621 Aug 202618 Nov 2026SOBI.ST 108Peer median 105
Six months, rebased to 100: Swedish Orphan Biovitrum against the median of its 20 peers (local-currency closes).

Swedish Orphan Biovitrum financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 32.0BSEK 28.2BSEK 26.0BSEK 22.1BSEK 18.8B
Revenue growth—+8%+18%+18%—
Gross profitSEK 21.6BSEK 18.8BSEK 16.6BSEK 14.1BSEK 12.3B
EBITDASEK 13.3BSEK 11.5BSEK 9.54BSEK 7.83BSEK 6.80B
Net incomeSEK 6.63BSEK 478MSEK 3.88BSEK 2.41BSEK 2.64B
Free cash flowSEK 7.87BSEK 8.53BSEK 7.22BSEK 4.06BSEK 4.59B
Capital expenditureSEK 1.32BSEK 3.15BSEK 3.00BSEK 4.94BSEK 1.48B
Total debtSEK 16.2BSEK 11.5BSEK 16.7BSEK 20.5BSEK 9.10B

Quarterly statements and history in the cockpit →

Swedish Orphan Biovitrum competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%JAZZORNAVEXELASND6446000538688506IPNTORNTPHARM1801LAURUSLABS6990ALNYZYDUSLIFEDRREDDY1177REC600436SOBI.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Swedish Orphan Biovitrum is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×500×1,000×JAZZORNAVEXELASND644645071801LAURUSLABS6990ALNYZYDUSLIFEDRREDDY600436SOBI.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Swedish Orphan Biovitrum is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%JAZZORNAVASND64464507TORNTPHARM1801LAURUSLABS6990ALNYDRREDDY600436SOBI.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Swedish Orphan Biovitrum is the large dot.

Swedish Orphan Biovitrum competitors and peer comparison

Head to head with its named competitors (SOBI.ST vs AZN.L vs RARE vs SAN.PA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Swedish Orphan Biovitrum SOBI.ST$16.1B+6%+15%30%24.1×-2.1%
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%
Ultragenyx Pharmaceutical RARE$1.81B-24%+16%-64%9.6×n/a
Sanofi SAN.PA$114B+13%+15%27%9.7×-4.8%

How Swedish Orphan Biovitrum compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Swedish Orphan Biovitrum against its 20 peers (data as of 18 Nov 2026)
MeasureSOBI.STPeer medianRank in peer set
1-month return+6.2%+5.7%10th highest of 21
6-month return+6.0%+4.4%8th highest of 21
Distance from 52-week high-6.5%-7.2%9th highest of 21
Revenue growth (TTM)+14.8%+18.8%11th highest of 21
Operating margin30.4%21.3%4th highest of 21
Forward P/E24.1×28.0×10th cheapest of 20
Growth the price implies (Req g, 7 yrs)-2.1%6.4%6th least demanding of 19
Growth delivered (Del g)+13.1%+12.3%8th highest of 19
Hurdle (Req g minus delivered)-15.2 pp-11.2 pp7th least demanding of 19
ROIC minus cost of capital+7.7 pp+7.3 pp11th highest of 21
EV / EBITDA13.4×18.5×6th cheapest of 17
Net debt / EBITDA1.1×-0.1×6th most indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Swedish Orphan Biovitrum SOBI.STSweden$16.1B+6%+15%30%24.1×-2.1%+13.1%
Jazz Pharmaceuticals Public JAZZUnited States$15.9B+4%+13%25%9.3×-2.8%+12.5%
Orion ORNAV.HEFinland$15.7B+41%+34%38%23.6×-6.2%+11.7%
Exelixis EXELUnited States$16.7B+37%+9%40%17.7×-3.8%+18.6%
Ascendis Pharma A/S ASNDUnited States$16.9B+12%+94%18%28.0×19.2%+152.4%
PharmaEssentia 6446.TWTaiwan$15.0B+67%+78%40%31.9×23.7%+94.8%
Yunnan Baiyao 000538.SZChina$15.0B+11%+5%11%18.3×-0.2%+4.7%
Sichuan Biokin Pharmaceutical 688506.SSChina$14.9B-7%+14%-43%n/an/an/a
Ipsen IPN.PAFrance$14.8B+1%+14%30%10.8×-6.7%+7.2%
Shionogi & 4507.TJapan$17.6B+3%+46%29%11.8×0.2%+11.0%
Torrent Pharmaceuticals TORNTPHARM.NSIndia$18.8B+3%+42%22%70.2×37.6%+11.3%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%52.3×11.6%+26.8%
Laurus Labs LAURUSLABS.NSIndia$13.4B+73%+23%24%76.4×51.2%+7.3%
Sichuan Kelun-Biotech Biopharmaceutical 6990.HKHong Kong$13.0B-1%+44%-38%1,176.1×55.3%+33.6%
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%21.2×0.5%+49.8%
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%30.0×n/an/a
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%32.0×30.7%+12.1%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%17.5×-5.7%+5.4%
Recordati REC.MIItaly$12.0B+3%+8%30%16.6×1.1%+12.6%
Zhangzhou Pientzehuang Pharmaceutical 600436.SSChina$11.6B-4%-19%19%40.7×24.9%+6.8%
Mankind Pharma MANKIND.NSIndia$11.6B+5%+13%21%44.4×28.6%+18.1%

Questions

Who are Swedish Orphan Biovitrum's main competitors?
Named competitors: Alexion (AstraZeneca) (AZN.L), Ultragenyx (RARE), Sanofi (hemophilia) (SAN.PA). The cockpit's measured peer set (industry) also includes Jazz Pharmaceuticals Public (JAZZ), Orion (ORNAV.HE), Exelixis (EXEL), Ascendis Pharma A/S (ASND), PharmaEssentia (6446.TW), Yunnan Baiyao (000538.SZ).
Is Swedish Orphan Biovitrum expensive compared with its peers?
On forward p/e it trades at 24.1× against a peer median of 28.0×, 10th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -15 pp: the price already allows for a slowdown.
How has Swedish Orphan Biovitrum stock performed?
Over six months to 18 Nov 2026 the shares returned +6.0% against +4.4% for the median peer; over one year +39.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.